poor ovarian response
Conditions
Interventions
Control group:Placebo
Experimental group:Herbal decoction
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Age
35 Years to 42 Years
Inclusion criteria
Inclusion criteria: (1)Female aged between 35 and 42 years. (2)Regular menstrual cycle with a cycle length of 21 to 35 days. (3)Meets the second and fourth subgroups of the Poor Ovarian Response Evaluation (POSEIDON) criteria. (4)Planning to undergo IVF-ET with an antagonist protocol for ovarian stimulation. (5)Meets the diagnostic criteria for Kidney Deficiency according to Traditional Chinese Medicine. (6)Voluntarily agrees to participate in this clinical trial and signs a written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Untreated hydrosalpinx endometriosis untreated uterine diseases (such as endometrial polyps intrauterine adhesions) or uterine fibroids larger than 4 cm. 2.History of recurrent implantation failure (defined as having undergone =3 transfers or having a total of 4-6 high-quality cleavage-stage embryos or =3 high-quality blastocysts that have failed). 3.BMI = 28 kg/m². 4.Abnormal liver or kidney function. 5.Male partner with severe or very severe oligospermia. 6.Not planning to undergo embryo transfer within six months. 7.Known allergy to the study medication. 8.Received Traditional Chinese Medicine treatment for poor ovarian response (such as Kuntai capsules Dingkun pills Tiaojing Chuyun pills Jinfeng pills Qilin pills or herbal decoctions containing Cuscuta Duhuo and Sangjisheng) within three months prior to enrollment. 9.Participated in other clinical trials within three months prior to enrollment. 10.Considered by the investigator to be unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of oocytes retrieved; | — |
Secondary
| Measure | Time frame |
|---|---|
| Luteinizing hormone on HCG day;Total amount of gonadotropin;Antral Follicle Count;TCM syndrome curative effect;Good quality embryo rate;Natural pregnancy and menstruation during medication;LH;Uterine thickness;Progesterone on the day of HCG;Positive rate of serum HCG;Clinical pregnancy rate;Live birth rate;Number of follicles on HCG day;Biochemical pregnancy rate;AMH;P;Gonadotropin days;Endometrial thickness and type on HCG day;Cancel the cycle number/rate;Types of Uterus;Uterine and Ovarian size;FSH;Estradiol on HCG day;E2; | — |
Countries
China
Contacts
Public ContactXiYan Xin
Peking University Third Hospital
Outcome results
None listed